Paratek Pharmaceuticals EBIT

Paratek Pharmaceuticals (PRTK) currently reports a EBIT of $-44M as of June 2023. That compares with $-68M in the prior-year period — up 34.7% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Paratek Pharmaceuticals's EBIT history and peer comparisons.

Paratek Pharmaceuticals's EBIT increased from $-68M to $-44M — a 34.7% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Paratek Pharmaceuticals's EBIT of $-44M is lower than the Healthcare sector average of $22B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Paratek Pharmaceuticals reported $-44M in EBIT as of June 2023. That compares with $-68M in the prior-year period — up 34.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-44M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Paratek Pharmaceuticals, and consider following PRTK for alerts when major investors trade the stock.